Inhibrx Biosciences, Inc. (INBX) Comparison with companies in other sectors?

Inhibrx Biosciences, Inc. has a share price of 14.48M. You can analyze Inhibrx Biosciences, Inc. (INBX) competitors across different market sectors through stock heatmaps.

What are INBX's NET and operating margins?

Inhibrx Biosciences, Inc. (INBX) operating margin is around -1502.62, and net profit margin is approximately 8614.85 as of the latest reports.

In what way does INBX's earnings per share (EPS) trend reflect its financial momentum?

Inhibrx Biosciences, Inc. (INBX) EPS is 119.02 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Inhibrx Biosciences, Inc. is 0.18, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Inhibrx Biosciences, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Inhibrx Biosciences, Inc. like P/E which is 0.20, P/B which is 3.56, and PEG which is -0.17. Compare them with sector averages to evaluate if the stock is priced fairly.

Inhibrx Biosciences, Inc.

INBX•NASDAQ

Healthcare

Biotechnology

$21.92

$0.52(2.43%)

Inhibrx Biosciences, Inc. (INBX) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$119.02

P/E Ratio

0.18

ROE

11.01%

Net Margin

8614.85%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$317.31M

Shares OutstandingTotal number of shares issued

$14.48M

Book Value/ShareNet worth per share

$6.11

Revenue/ShareAnnual revenue per share

$0.01

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$119.02

Net MarginNet income as percentage of revenue

861485.50%

Operating MarginOperating income as percentage of revenue

-150262.00%

ROEReturn on shareholders' equity

1101.19%

ROAReturn on total assets

710.10%

ROCEReturn on capital employed

-151.02%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-10.91

Cash/ShareCash and equivalents per share

$14.00

FCF YieldFree cash flow as percentage of market cap

-53.43%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for INBXFinancial Ratios Analysis details for INBX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for INBXSector Benchmarking details for INBX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Inhibrx Biosciences, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Inhibrx Biosciences, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Inhibrx Biosciences, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Inhibrx Biosciences, Inc.

For Inhibrx Biosciences, Inc., essential financial indicators include EPS 119.02, PE 0.18, and ROE 11.01. These key ratios reveal insights into Inhibrx Biosciences, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Inhibrx Biosciences, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Inhibrx Biosciences, Inc.

Metrics like Net Margin 861485.50% and ROA 710.10% shed light on how well Inhibrx Biosciences, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Inhibrx Biosciences, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Inhibrx Biosciences, Inc.

Using ratios such as P/B Ratio 3.56 and PEG Ratio -0.17, investors can assess whether Inhibrx Biosciences, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Inhibrx Biosciences, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Inhibrx Biosciences, Inc.

Financial health indicators, such as Debt/Equity Ratio 1.13 and Cash Flow $-10.91, provide a snapshot of Inhibrx Biosciences, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Inhibrx Biosciences, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Inhibrx Biosciences, Inc.

Investing in Inhibrx Biosciences, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Inhibrx Biosciences, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;